CG Oncology, Inc. to Post FY2024 Earnings of ($1.77) Per Share, Lifesci Capital Forecasts (NASDAQ:CGON)

CG Oncology, Inc. (NASDAQ:CGON - Free Report) - Equities researchers at Lifesci Capital dropped their FY2024 earnings estimates for CG Oncology in a research report issued to clients and investors on Tuesday, April 23rd. Lifesci Capital analyst S. Slutsky now forecasts that the company will post earnings of ($1.77) per share for the year, down from their previous estimate of ($1.75). The consensus estimate for CG Oncology's current full-year earnings is ($1.59) per share. Lifesci Capital also issued estimates for CG Oncology's FY2025 earnings at ($2.11) EPS and FY2026 earnings at ($1.22) EPS.

Several other equities research analysts have also recently commented on CGON. The Goldman Sachs Group assumed coverage on shares of CG Oncology in a research report on Tuesday, February 20th. They issued a "neutral" rating and a $42.00 price target on the stock. Cantor Fitzgerald started coverage on CG Oncology in a report on Tuesday, February 20th. They set an "overweight" rating and a $75.00 price objective on the stock. HC Wainwright reiterated a "buy" rating and issued a $75.00 target price on shares of CG Oncology in a report on Thursday, April 4th. Finally, Morgan Stanley started coverage on CG Oncology in a report on Tuesday, February 20th. They issued an "overweight" rating and a $55.00 target price on the stock.

CG Oncology Trading Up 0.4 %

CG Oncology stock traded up $0.15 during midday trading on Thursday, hitting $36.20. The company's stock had a trading volume of 183,717 shares, compared to its average volume of 615,443. The business's 50-day simple moving average is $40.54. CG Oncology has a 12 month low of $28.55 and a 12 month high of $50.23.

Insider Buying and Selling

In other news, major shareholder Decheng Capital Global Life Sc acquired 400,000 shares of the firm's stock in a transaction that occurred on Monday, January 29th. The stock was acquired at an average cost of $19.00 per share, with a total value of $7,600,000.00. Following the acquisition, the insider now owns 400,000 shares in the company, valued at $7,600,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, CFO Corleen M. Roche bought 2,000 shares of the business's stock in a transaction that occurred on Monday, January 29th. The stock was purchased at an average cost of $19.00 per share, for a total transaction of $38,000.00. Following the purchase, the chief financial officer now directly owns 2,000 shares in the company, valued at $38,000. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Decheng Capital Global Life Sc bought 400,000 shares of the business's stock in a transaction that occurred on Monday, January 29th. The shares were bought at an average price of $19.00 per share, with a total value of $7,600,000.00. Following the completion of the purchase, the insider now owns 400,000 shares in the company, valued at $7,600,000. The disclosure for this purchase can be found here. In the last three months, insiders bought 666,472 shares of company stock valued at $12,662,968.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.